HK1201733A1 - Administration of nedd8-activating enzyme inhibitor and hypomethylating agent nedd8- - Google Patents
Administration of nedd8-activating enzyme inhibitor and hypomethylating agent nedd8-Info
- Publication number
- HK1201733A1 HK1201733A1 HK15102294.2A HK15102294A HK1201733A1 HK 1201733 A1 HK1201733 A1 HK 1201733A1 HK 15102294 A HK15102294 A HK 15102294A HK 1201733 A1 HK1201733 A1 HK 1201733A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- nedd8
- administration
- enzyme inhibitor
- activating enzyme
- hypomethylating agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555049P | 2011-11-03 | 2011-11-03 | |
| PCT/US2012/063382 WO2013067396A2 (en) | 2011-11-03 | 2012-11-02 | Administration of nedd8-activating enzyme inhibitor and hypomethylating agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1201733A1 true HK1201733A1 (en) | 2015-09-11 |
Family
ID=48193039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15102294.2A HK1201733A1 (en) | 2011-11-03 | 2015-03-06 | Administration of nedd8-activating enzyme inhibitor and hypomethylating agent nedd8- |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8980850B2 (pl) |
| EP (1) | EP2773360B1 (pl) |
| JP (2) | JP6231988B2 (pl) |
| KR (1) | KR101987861B1 (pl) |
| CN (1) | CN104245699B (pl) |
| AU (1) | AU2012321106C1 (pl) |
| BR (1) | BR112014010699B1 (pl) |
| CA (1) | CA2854461C (pl) |
| EA (1) | EA028380B1 (pl) |
| ES (1) | ES2668272T3 (pl) |
| GE (1) | GEP20196940B (pl) |
| HK (1) | HK1201733A1 (pl) |
| IL (1) | IL232353B (pl) |
| MA (1) | MA35662B1 (pl) |
| MX (1) | MX357835B (pl) |
| MY (1) | MY176125A (pl) |
| PL (1) | PL2773360T3 (pl) |
| SG (1) | SG11201401895WA (pl) |
| TN (1) | TN2014000194A1 (pl) |
| TR (1) | TR201807342T4 (pl) |
| UA (1) | UA114414C2 (pl) |
| WO (1) | WO2013067396A2 (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20120907A1 (es) | 2009-05-14 | 2012-08-18 | Millennium Pharm Inc | Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato |
| CN103889988B (zh) * | 2011-08-24 | 2018-05-04 | 米伦纽姆医药公司 | Nedd8-活化酶的抑制剂 |
| EP2764866A1 (en) * | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| WO2014186388A2 (en) | 2013-05-14 | 2014-11-20 | Millennium Pharmaceutcals, Inc. | Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents |
| JP2016525531A (ja) * | 2013-07-26 | 2016-08-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 急性骨髄性白血病及び骨髄異形成症候群の処置のためのアザシチジンと組み合わせたボラセルチブ |
| CN106659765B (zh) | 2014-04-04 | 2021-08-13 | 德玛医药 | 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途 |
| CN103948590A (zh) * | 2014-05-22 | 2014-07-30 | 中国药科大学 | Nedd8激活酶抑制剂及其医药用途 |
| NZ741433A (en) * | 2015-10-15 | 2024-07-26 | Celgene Corp | Combination therapy for treating malignancies |
| US11701406B2 (en) | 2017-05-25 | 2023-07-18 | The Board Of Trustees Of The Leland Stanford Junior University | Combination of low dose IL-2 and an inhibitor of Treg IL-2R desensitization to treat autoimmune and allergic inflammatory diseases |
| WO2019060536A1 (en) * | 2017-09-21 | 2019-03-28 | Millennium Pharmaceuticals, Inc. | CO-CRYSTALLINE FORMS OF ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-DIHYDRO-1H-INDEN-1-YLAMINO] -7H-PYRROLO [2,3-D] PYRIMIDIN -7-YL} -2-HYDROXYCYCLOPENTYL) METHYLSULFAMATE, THEIR FORMULATIONS AND USES |
| AU2019384547A1 (en) * | 2018-11-20 | 2021-06-03 | Fulcrum Therapeutics, Inc. | Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease |
| EP3938050A1 (en) | 2019-03-15 | 2022-01-19 | Fulcrum Therapeutics, Inc. | Macrocyclic azolopyridine derivatives as eed and prc2 modulators |
| WO2023025668A1 (en) | 2021-08-25 | 2023-03-02 | Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune | Methods for the generation of stem cell memory t cells for adoptive t cell therapy |
| WO2023242235A1 (en) * | 2022-06-14 | 2023-12-21 | Scandion Oncology A/S | Abcg2 inhibitor and nae inhibitor for the treatment of cancer |
| CN115007323B (zh) * | 2022-06-17 | 2024-01-23 | 中南大学 | 一种抑制矿物中黄铁矿浮选的方法 |
| WO2024012414A1 (en) * | 2022-07-11 | 2024-01-18 | Westlake University | Use of a fbxo42 specific inhibitor in treating notch signaling-dependent disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6943249B2 (en) | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
| US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
| US20060063735A1 (en) | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
| US20060128654A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
| SI1848718T1 (sl) | 2005-02-04 | 2012-12-31 | Millennium Pharmaceuticals, Inc. | Inhibitorji E1 aktivacijskih enzimov |
| EP1989206B1 (en) | 2006-02-02 | 2012-07-04 | Millennium Pharmaceuticals, Inc. | Inhibitors of e1 activating enzyme |
| MY157177A (en) * | 2006-08-08 | 2016-05-13 | Millennium Pharm Inc | Heteroaryl compounds useful as inhibitors of e1 activating enzymes |
| WO2008028193A2 (en) | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
| JP2011505336A (ja) | 2007-11-01 | 2011-02-24 | セルジーン コーポレイション | 骨髄異形成症候群治療のためのシチジンアナログ |
| EP2257310A2 (en) * | 2008-02-26 | 2010-12-08 | Nerviano Medical Sciences S.r.l. | Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents |
| WO2009139888A1 (en) | 2008-05-15 | 2009-11-19 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
| CA2725295C (en) * | 2008-06-09 | 2016-11-08 | Cyclacel Limited | Combination of sapacitabine (cndac) and dna methyltransferase inhibitors such as decitabine and procaine |
| EP2410987B1 (en) * | 2009-03-23 | 2018-05-16 | Ambit Biosciences Corporation | Methods of treatment using combination therapy |
| PE20120907A1 (es) | 2009-05-14 | 2012-08-18 | Millennium Pharm Inc | Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato |
| CN103338753A (zh) | 2011-01-31 | 2013-10-02 | 细胞基因公司 | 胞苷类似物的药物组合物及其使用方法 |
| US9125884B2 (en) | 2011-11-01 | 2015-09-08 | Celgene Corporation | Methods for treating cancers using oral formulations of cytidine analogs |
-
2012
- 2012-11-02 UA UAA201405842A patent/UA114414C2/uk unknown
- 2012-11-02 PL PL12844799T patent/PL2773360T3/pl unknown
- 2012-11-02 SG SG11201401895WA patent/SG11201401895WA/en unknown
- 2012-11-02 TR TR2018/07342T patent/TR201807342T4/tr unknown
- 2012-11-02 ES ES12844799.2T patent/ES2668272T3/es active Active
- 2012-11-02 WO PCT/US2012/063382 patent/WO2013067396A2/en active Application Filing
- 2012-11-02 BR BR112014010699-1A patent/BR112014010699B1/pt not_active IP Right Cessation
- 2012-11-02 CN CN201280062112.9A patent/CN104245699B/zh active Active
- 2012-11-02 MY MYPI2014001239A patent/MY176125A/en unknown
- 2012-11-02 MX MX2014005323A patent/MX357835B/es active IP Right Grant
- 2012-11-02 JP JP2014540146A patent/JP6231988B2/ja active Active
- 2012-11-02 EA EA201400539A patent/EA028380B1/ru not_active IP Right Cessation
- 2012-11-02 KR KR1020147014236A patent/KR101987861B1/ko active IP Right Grant
- 2012-11-02 CA CA2854461A patent/CA2854461C/en not_active Expired - Fee Related
- 2012-11-02 EP EP12844799.2A patent/EP2773360B1/en active Active
- 2012-11-02 GE GEAP201213483A patent/GEP20196940B/en unknown
- 2012-11-02 US US13/667,641 patent/US8980850B2/en active Active
- 2012-11-02 AU AU2012321106A patent/AU2012321106C1/en not_active Ceased
-
2014
- 2014-04-29 IL IL232353A patent/IL232353B/en active IP Right Grant
- 2014-04-30 TN TNP2014000194A patent/TN2014000194A1/en unknown
- 2014-05-26 MA MA37066A patent/MA35662B1/fr unknown
-
2015
- 2015-01-23 US US14/603,717 patent/US20150366886A1/en not_active Abandoned
- 2015-03-06 HK HK15102294.2A patent/HK1201733A1/xx unknown
-
2017
- 2017-10-20 JP JP2017203560A patent/JP2018009035A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1201733A1 (en) | Administration of nedd8-activating enzyme inhibitor and hypomethylating agent nedd8- | |
| HRP20180953T1 (hr) | Supstituirani 3-haloalilaminski inhibitori za ssao i njihove uporabe | |
| HK1246674A1 (zh) | 犬尿氨酸-3-單加氧酶抑制劑、藥物組合物及其使用方法 | |
| HK1199726A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3- | |
| HK1203853A1 (en) | Inhibitors of arginase and their therapeutic applications | |
| EP2678018A4 (en) | COMBINATION OF CHINESE HEMMER AND USES THEREOF | |
| HK1202244A1 (en) | Prebiotic formulations and methods of use | |
| HK1202112A1 (en) | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase | |
| EP2721019A4 (en) | THERAPEUTIC ACTIVE COMPOSITIONS AND METHOD FOR THEIR USE | |
| HK1198619A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3- | |
| EP2790709A4 (en) | HEMOSTATIC ACTIVE SUBSTANCES AND METHOD OF USE THEREOF | |
| IL232115A0 (en) | Pharmaceutical preparations that include dgla and/or 15-hetre and methods of using them | |
| EP2635287A4 (en) | NEDD8 ACTIVATOR ENZYME INHIBITOR ADMINISTRATION | |
| HK1201066A1 (en) | Pyranopyridone inhibitors of tankyrase | |
| EP2688901A4 (en) | INHIBITORS OF 17SS-HSD1, 17SS-HSD3 AND 17SS-HSD10 |